Co-delivery of the NKT agonist α-galactosylceramide and tumor antigens to cross-priming dendritic cells breaks tolerance to self-antigens and promotes antitumor responses

Vaccines designed to abrogate the tolerance of tumor self-antigens and amplify cytotoxic CD8(+) T cells (CTLs) have promise for the treatment of cancer. Type I natural killer (NKT) cells have attracted considerable interest in the cancer therapy field. In the current study, we have exploited the uni...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncoimmunology
Главные авторы: Ghinnagow, Reem, De Meester, Julie, Cruz, Luis Javier, Aspord, Caroline, Corgnac, Stéphanie, Macho-Fernandez, Elodie, Soulard, Daphnée, Fontaine, Josette, Chaperot, Laurence, Charles, Julie, Soncin, Fabrice, Mami-Chouaib, Fathia, Plumas, Joel, Faveeuw, Christelle, Trottein, François
Формат: Artigo
Язык:Inglês
Опубликовано: Taylor & Francis 2017
Предметы:
Original Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5599097/
https://ncbi.nlm.nih.gov/pubmed/28932640
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1339855
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы